Brief: NGM Bio’S Ngm621 Receives Fast Track Designation From The FDA For The Treatment Of Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
07/02/2022 13:10
Feb 7 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO’S NGM621 RECEIVES FAST TRACK DESIGNATION FROM THE
FDA
FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY
TO AGE-RELATED MACULAR DEGENERATION
* NGM BIOPHARMACEUTICALS INC - CURRENTLY EVALUATING NGM621
IN ITS
ONGOING PHASE 2 CATALINA STUDY AND A TOPLINE DATA READOUT IS
EXPECTED IN Q4 OF 2022
* NGM BIOPHARMACEUTICALS INC - CURRENTLY EVALUATING NGM621
IN ITS
ONGOING PHASE 2 CATALINA STUDY AND A TOPLINE DATA READOUT IS
EXPECTED IN Q4 OF 2022
Source text for Eikon: ID:nGNX9B9GVn
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors